Gyre Therapeutics (GYRE) Receivables - Net (2010 - 2026)
Gyre Therapeutics (GYRE) reported Receivables - Net of $26.6 million for Q1 2026, up 29.36% year-over-year from $20.5 million in Q1 2025, and down 14.89% on a QoQ basis from $31.2 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Receivables - Net data on file, last reported at $26.6 million in Q1 2026.
- Quarterly Receivables - Net rose 29.36% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (up 29.36% YoY) and the FY2025 annual result came in at $31.2 million, up 57.74% from the prior year.
- Receivables - Net retreated to $26.6 million in Q1 2026 per GYRE's latest filing, from $31.2 million in the prior quarter.
- Across five years, Receivables - Net topped out at $31.2 million in Q4 2025 and bottomed at $564000.0 in Q1 2022.
- The 5-year median for Receivables - Net is $18.6 million (2024), against an average of $16.7 million.
- Peak annual rise in Receivables - Net reached 842.57% in 2022, while the deepest fall reached 43.94% in 2022.
- Tracing GYRE's Receivables - Net over 5 years: stood at $17.1 million in 2022, then slipped by 11.51% to $15.2 million in 2023, then jumped by 30.57% to $19.8 million in 2024, then jumped by 57.74% to $31.2 million in 2025, then slipped by 14.89% to $26.6 million in 2026.
- Per Business Quant, the three latest GYRE Receivables - Net figures stand at $26.6 million (Q1 2026), $31.2 million (Q4 2025), and $26.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.58 Mn |
| Mar 31, 2026 | 26.58 Mn |
| Dec 31, 2025 | 31.23 Mn |
| Dec 31, 2025 | 31.23 Mn |
| Sep 30, 2025 | 26.06 Mn |
| Sep 30, 2025 | 26.06 Mn |
| Jun 30, 2025 | 24.86 Mn |
| Jun 30, 2025 | 24.86 Mn |
| Mar 31, 2025 | 20.55 Mn |
| Mar 31, 2025 | 20.55 Mn |
| Dec 31, 2024 | 19.80 Mn |
| Dec 31, 2024 | 19.80 Mn |
| Sep 30, 2024 | 19.54 Mn |
| Sep 30, 2024 | 19.54 Mn |
| Jun 30, 2024 | 18.62 Mn |
| Jun 30, 2024 | 18.62 Mn |
| Mar 31, 2024 | 15.46 Mn |
| Mar 31, 2024 | 15.46 Mn |
| Dec 31, 2023 | 15.16 Mn |
| Dec 31, 2023 | 15.16 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 17.14 Mn |
| Dec 31, 2022 | 17.14 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 564,000.00 |
| Mar 31, 2022 | 564,000.00 |
| Dec 31, 2021 | 1.82 Mn |
| Dec 31, 2021 | 1.82 Mn |
| Sep 30, 2021 | 1.11 Mn |
| Sep 30, 2021 | 1.11 Mn |
| Jun 30, 2021 | 1.97 Mn |
| Jun 30, 2021 | 1.97 Mn |
| Mar 31, 2021 | 1.01 Mn |
| Mar 31, 2021 | 1.01 Mn |
| Dec 31, 2020 | 3.31 Mn |
| Dec 31, 2020 | 3.31 Mn |
| Sep 30, 2020 | 1.56 Mn |
| Sep 30, 2020 | 1.56 Mn |
| Jun 30, 2020 | 1.99 Mn |
| Jun 30, 2020 | 1.99 Mn |
| Mar 31, 2020 | 1.37 Mn |
| Mar 31, 2020 | 1.37 Mn |
| Dec 31, 2019 | 15.00 Mn |
| Dec 31, 2019 | 15.00 Mn |
| Dec 31, 2018 | 10,000.00 |
| Dec 31, 2018 | 10,000.00 |
| Dec 31, 2017 | 24,000.00 |
| Dec 31, 2017 | 24,000.00 |
| Sep 30, 2017 | 52,000.00 |
| Sep 30, 2017 | 52,000.00 |
| Jun 30, 2017 | 135,000.00 |
| Jun 30, 2017 | 135,000.00 |
| Mar 31, 2017 | 227,000.00 |
| Mar 31, 2017 | 227,000.00 |
| Dec 31, 2016 | 31,000.00 |
| Dec 31, 2016 | 31,000.00 |
| Sep 30, 2016 | 101,000.00 |
| Sep 30, 2016 | 101,000.00 |
| Jun 30, 2016 | 462,000.00 |
| Jun 30, 2016 | 462,000.00 |
| Mar 31, 2016 | 448,000.00 |
| Mar 31, 2016 | 448,000.00 |
| Dec 31, 2015 | 492,000.00 |
| Dec 31, 2015 | 492,000.00 |
| Sep 30, 2015 | 648,000.00 |
| Sep 30, 2015 | 648,000.00 |
| Jun 30, 2015 | 10,000.00 |
| Jun 30, 2015 | 10,000.00 |
| Mar 31, 2015 | 68,000.00 |
| Mar 31, 2015 | 68,000.00 |
| Dec 31, 2014 | 95,000.00 |
| Dec 31, 2014 | 95,000.00 |
| Sep 30, 2014 | 57,000.00 |
| Sep 30, 2014 | 57,000.00 |
| Jun 30, 2014 | 28,000.00 |
| Jun 30, 2014 | 28,000.00 |
| Mar 31, 2014 | 343,000.00 |
| Mar 31, 2014 | 343,000.00 |
| Dec 31, 2013 | 278,000.00 |
| Dec 31, 2013 | 278,000.00 |
| Jun 30, 2013 | 108,000.00 |
| Jun 30, 2013 | 108,000.00 |
| Mar 31, 2013 | 383,000.00 |
| Mar 31, 2013 | 383,000.00 |
| Dec 31, 2012 | 1.38 Mn |
| Dec 31, 2012 | 1.38 Mn |
| Sep 30, 2012 | 2.55 Mn |
| Sep 30, 2012 | 2.55 Mn |
| Jun 30, 2012 | 347,000.00 |
| Jun 30, 2012 | 347,000.00 |
| Mar 31, 2012 | 319,000.00 |
| Mar 31, 2012 | 319,000.00 |
| Dec 31, 2011 | 218,000.00 |
| Dec 31, 2011 | 218,000.00 |
| Sep 30, 2011 | 625,000.00 |
| Sep 30, 2011 | 625,000.00 |
| Jun 30, 2011 | 546,000.00 |
| Jun 30, 2011 | 546,000.00 |
| Dec 31, 2010 | 838,000.00 |
| Dec 31, 2010 | 838,000.00 |